Medicines Evaluation Unit

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Asthma3 trials
• Psoriasis3 trials
• COPD1 trial
• Cytomegalovirus infection1 trial
• Idiopathic pulmonary fibrosis1 trial

Phase

• Phase 15 trials
• Phase 23 trials
• Phase 1/21 trial

Status

• Completed7 trials
• Recruiting2 trials

Lead sponsor

• AeroRx Therapeutics Inc.1 trial
• Arxx Therapeutics1 trial
• CSL Behring1 trial
• DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company1 trial
• Kinaset Therapeutics Inc1 trial
• and 4 more

Running trials

• Recruiting

  Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients

  NCT07896252· Phase 2· AeroRx Therapeutics Inc.· Source

  Contact: Study Director Medical Director

• Recruiting

  RIG 101 Trial in Healthy Adults and Adults With Asthma

  NCT07488897· Phase 1/2· RIGImmune Inc.· Source

  Contact: MEU team

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• COPD1 recruiting

Closed trials

• Completed

  A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants

  NCT06145178· Phase 1· SpyBiotech Limited· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis

  NCT05896527· Phase 2· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Source

• Completed

  A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

  NCT05965089· Phase 1· Arxx Therapeutics· Source

• Completed

  Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685

  NCT05332704· Phase 1· Ono Pharmaceutical Co., Ltd.· Source

• Completed

  Single and Multiple Ascending Dose Study of KN-002

  NCT05006521· Phase 1· Kinaset Therapeutics Inc· Source

• Completed

  Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF

  NCT04533022· Phase 2· Vicore Pharma AB· Source

• Completed

  A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

  NCT04082754· Phase 1· CSL Behring· Source